Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an angel+ financing round. The round was led by INCE Capital and included contributions from Life Science Park Innovation Investment Fund and Witruth Capital. The proceeds will be used to advance the pre-clinical and clinical development of its product pipelines on a global scale.
Company Background
Since its founding in November 2021, Bennu Bio has accumulated hundreds of millions of RMB in funding, backed by GL Ventures and CDBI Partners. The T-cell therapy company has its first product, BEN101, prepared for clinical trials, with production process development and pharmacological and toxicological experiments already underway.
Funding Details
The latest angel+ round, led by INCE Capital, will support Bennu Bio’s efforts to develop its product pipelines globally. The company plans to use the funds to accelerate pre-clinical and clinical development, aiming to bring innovative cell therapies to patients worldwide.-Fineline Info & Tech
